The combination therapy of BRAF inhibitor Dabrafenib and the MEK inhibitor Trametinib is the approved first-line therapy for BRAF V600E-positive NSCLC patients [89,90]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.